Archive

In November last year, we published a ground-breaking article to Chemical Research in Toxicology titled ‘What Makes a Potent Nitrosamine? Statistical Validation of Expert-Derived Structure–Activity Relationships’.  

Within the paper, we show that certain structural features, when treated independently, have a statistically significant impact on the carcinogenic potency of nitrosamines. It is with great excitement that we share this publication making it to Chemical Research in Toxicology’s top 20 most downloaded articles, as well as being the most viewed article within their November edition. 

In our first blog of 2023, Chris Barber (our CEO) shares his thoughts on our 2022 success, BHAG* progress, and more. 

*We explain BHAG in the article, just in case you are wondering…

Hola! My name is Jessica Magallanes-Castaneda. I am originally from Mexico and moved to the UK in 2015 to pursue my MSc and PhD in Computer Science at The University of Sheffield. Keep reading on to see my typical day as a Software Developer at Lhasa!

Hello, my name is Oana Leonte, and I work in the Business Support Team at Lhasa Limited as a Business Support Manager.

In my role I provide support to many different functions across the organisation, this includes our Marketing, Applied Sciences and Business Partnerships teams. My role is very varied and relies on attention to detail and organisational skills to accommodate travel bookings and events planning, amongst other areas of support.

Read on to discover what a day in the life of a Business Support Manager at Lhasa can look like!

Mutagenic impurities can be expected in any drug product; however, this is not a concern providing they are present below the safe limit. The objective of a carcinogenicity study is to identify compounds that can cause tumours in animals, which is imperative to understanding the cancer risk posed to humans.

We are absolutely thrilled to have won theTech4Good (Product) award at the 2022 Leeds Digital Festival!

Read what one of our Complex Nitrosamines Data Sharing Initiative members, Graham Smith, Oncology Chemical Toxicology Lead at AstraZeneca, has to say about being involved in this growing consortium!

Hi, my name is Raeesah and I work in the Business Partnerships Team here at Lhasa Limited!

Read on to discover what a typical day in the life of a Business Partnerships Manager working from home on a Tuesday looks like!

Evaluating the potential toxicity of chemicals is an important part of the drug development process. Optimizing a data set that provides quality over quantity is critical in the search for suitable drug candidates. 

I recently read that by 2025, 36% of world data will be healthcare data. (Yes, thirty-six percent!). Considering this statistic, now more than ever, it is important that we are working to ensure existing data is utilised to make better safety assessment decisions more quickly - whilst also relying less on animal testing.